Novel agents in ovarian cancer

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

The standard treatment for epithelial ovarian cancer remains surgical debulking and chemotherapy with carboplatin and paclitaxel. However, the majority of patients relapse, and few, if any, achieve a cure. Future advancement in treatment should aim at targeting the biology of the disease, specifically mechanisms critical to tumor initiation and progression. Several Phase I and II clinical trials have identified novel opportunities for therapy. The most promising venues appear to be the antiangiogenic agents and the inhibitors of intracellular signaling. Novel modalities of delivering cytotoxics to tumor cells by exploiting ovarian cancer-specific biomarkers are also being tested, and appear promising. Immunomodulatory agents are being developed for consolidation therapy. Although devoid of the common side effects associated with chemotherapy, the use of targeted agents is associated with specific toxicities, related to the biological processes they block. The main challenge for future successful clinical development will be defining molecular markers predictive of response and judicious patient selection based on the biological features of the tumor. Individualized treatment driven by molecular characteristics will open the door to a new age in anticancer meclicine.

Original languageEnglish (US)
Pages (from-to)1227-1239
Number of pages13
JournalExpert Opinion on Investigational Drugs
Volume16
Issue number8
DOIs
StatePublished - Aug 1 2007

Fingerprint

Ovarian Neoplasms
Biological Phenomena
Therapeutics
Drug Therapy
Neoplasms
Phase II Clinical Trials
Clinical Trials, Phase I
Angiogenesis Inhibitors
Carboplatin
Tumor Biomarkers
Paclitaxel
Patient Selection
Recurrence

Keywords

  • Angiogenisis
  • Biological agents
  • Clinical trials
  • Ovarian cancer
  • Phase I
  • Phase II
  • Targeted treatment

ASJC Scopus subject areas

  • Pharmacology

Cite this

Novel agents in ovarian cancer. / Matei, Daniela.

In: Expert Opinion on Investigational Drugs, Vol. 16, No. 8, 01.08.2007, p. 1227-1239.

Research output: Contribution to journalReview article

@article{664cb254d659472b9cc9faa2c1351b4a,
title = "Novel agents in ovarian cancer",
abstract = "The standard treatment for epithelial ovarian cancer remains surgical debulking and chemotherapy with carboplatin and paclitaxel. However, the majority of patients relapse, and few, if any, achieve a cure. Future advancement in treatment should aim at targeting the biology of the disease, specifically mechanisms critical to tumor initiation and progression. Several Phase I and II clinical trials have identified novel opportunities for therapy. The most promising venues appear to be the antiangiogenic agents and the inhibitors of intracellular signaling. Novel modalities of delivering cytotoxics to tumor cells by exploiting ovarian cancer-specific biomarkers are also being tested, and appear promising. Immunomodulatory agents are being developed for consolidation therapy. Although devoid of the common side effects associated with chemotherapy, the use of targeted agents is associated with specific toxicities, related to the biological processes they block. The main challenge for future successful clinical development will be defining molecular markers predictive of response and judicious patient selection based on the biological features of the tumor. Individualized treatment driven by molecular characteristics will open the door to a new age in anticancer meclicine.",
keywords = "Angiogenisis, Biological agents, Clinical trials, Ovarian cancer, Phase I, Phase II, Targeted treatment",
author = "Daniela Matei",
year = "2007",
month = "8",
day = "1",
doi = "10.1517/13543784.16.8.1227",
language = "English (US)",
volume = "16",
pages = "1227--1239",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
number = "8",

}

TY - JOUR

T1 - Novel agents in ovarian cancer

AU - Matei, Daniela

PY - 2007/8/1

Y1 - 2007/8/1

N2 - The standard treatment for epithelial ovarian cancer remains surgical debulking and chemotherapy with carboplatin and paclitaxel. However, the majority of patients relapse, and few, if any, achieve a cure. Future advancement in treatment should aim at targeting the biology of the disease, specifically mechanisms critical to tumor initiation and progression. Several Phase I and II clinical trials have identified novel opportunities for therapy. The most promising venues appear to be the antiangiogenic agents and the inhibitors of intracellular signaling. Novel modalities of delivering cytotoxics to tumor cells by exploiting ovarian cancer-specific biomarkers are also being tested, and appear promising. Immunomodulatory agents are being developed for consolidation therapy. Although devoid of the common side effects associated with chemotherapy, the use of targeted agents is associated with specific toxicities, related to the biological processes they block. The main challenge for future successful clinical development will be defining molecular markers predictive of response and judicious patient selection based on the biological features of the tumor. Individualized treatment driven by molecular characteristics will open the door to a new age in anticancer meclicine.

AB - The standard treatment for epithelial ovarian cancer remains surgical debulking and chemotherapy with carboplatin and paclitaxel. However, the majority of patients relapse, and few, if any, achieve a cure. Future advancement in treatment should aim at targeting the biology of the disease, specifically mechanisms critical to tumor initiation and progression. Several Phase I and II clinical trials have identified novel opportunities for therapy. The most promising venues appear to be the antiangiogenic agents and the inhibitors of intracellular signaling. Novel modalities of delivering cytotoxics to tumor cells by exploiting ovarian cancer-specific biomarkers are also being tested, and appear promising. Immunomodulatory agents are being developed for consolidation therapy. Although devoid of the common side effects associated with chemotherapy, the use of targeted agents is associated with specific toxicities, related to the biological processes they block. The main challenge for future successful clinical development will be defining molecular markers predictive of response and judicious patient selection based on the biological features of the tumor. Individualized treatment driven by molecular characteristics will open the door to a new age in anticancer meclicine.

KW - Angiogenisis

KW - Biological agents

KW - Clinical trials

KW - Ovarian cancer

KW - Phase I

KW - Phase II

KW - Targeted treatment

UR - http://www.scopus.com/inward/record.url?scp=34548237539&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548237539&partnerID=8YFLogxK

U2 - 10.1517/13543784.16.8.1227

DO - 10.1517/13543784.16.8.1227

M3 - Review article

C2 - 17685871

AN - SCOPUS:34548237539

VL - 16

SP - 1227

EP - 1239

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 8

ER -